A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.
Pain, Cancer
DRUG: Placebo|DRUG: KW-2246 (fentanyl citrate)
This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.